Xilio Therapeutics, Inc. Common Stock (XLO)
PHARMACEUTICAL PREPARATIONS
Xilio Therapeutics, Inc. Common Stock (XLO) is listed on Nasdaq, where it has traded since October 22, 2021.
- Listed On
- Nasdaq
- Listed Since
- October 22, 2021
- Employees
- 76
- Market Cap
- $53M
About Xilio Therapeutics, Inc. Common Stock
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 25 institutions reported holding XLO, with 3.4 million shares worth $32.6 million in aggregate. The largest reported holder was Bain Capital Life Sciences Investors, with 664,021 shares worth $6.4 million. Of the 5 largest holders listed below, 1 opened a new position in XLO, 1 added shares and 3 held their positions unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Bain Capital Life Sciences Investors | 664,021 | $6M | Unchanged |
| Gilead Sciences | 650,389 | $6M | Unchanged |
| Orbimed Advisors | 592,300 | $6M | New position |
| Frazier Life Sciences Management | 422,505 | $4M | Unchanged |
| Stonepine Capital Management | 225,994 | $2M | Added 252.22% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is XLO?
Xilio Therapeutics, Inc. Common Stock (XLO) is listed on Nasdaq, where it has traded since October 22, 2021.
Who are the largest institutional holders of XLO?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of XLO were Bain Capital Life Sciences Investors, Gilead Sciences and Orbimed Advisors.
How many institutions own XLO?
25 institutions reported a position in XLO for the quarter ended June 30, 2026, worth $32.6 million in total.
Did institutions buy or sell XLO last quarter?
Of the 5 largest reported holders, 1 opened a new position in XLO, 1 added shares and 3 held their positions unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for XLO.
Every reported institutional holder, plus insider and congressional trades in XLO, on SentiSense.